OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Cost-Effectiveness of Prefusion F Protein-Based Vaccines Against Respiratory Syncytial Virus Disease for Older Adults in the United States
Seyed M. Moghadas, Affan Shoukat, Carolyn E. Bawden, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 10
Seyed M. Moghadas, Affan Shoukat, Carolyn E. Bawden, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 10
Showing 10 citing articles:
Impact and cost-effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: A Canadian Immunization Research Network (CIRN) study
Affan Shoukat, Carolyn E. Bawden, Gergely Röst, et al.
Vaccine (2024) Vol. 42, Iss. 7, pp. 1768-1776
Open Access | Times Cited: 8
Affan Shoukat, Carolyn E. Bawden, Gergely Röst, et al.
Vaccine (2024) Vol. 42, Iss. 7, pp. 1768-1776
Open Access | Times Cited: 8
Two Recombinant Cytomegalovirus Antigens Formulated with the SPA14 Adjuvant System: Impact of Temperature, pH and Excipients on the Stability of each Antigen and Adjuvant Component
John M. Hickey, Ozan S. Kumru, François Dalençon, et al.
Journal of Pharmaceutical Sciences (2025)
Open Access
John M. Hickey, Ozan S. Kumru, François Dalençon, et al.
Journal of Pharmaceutical Sciences (2025)
Open Access
Cost-effectiveness of vaccinating adults aged 60 years and older against respiratory syncytial virus
David W. Hutton, Lisa A. Prosser, Angela M. Rose, et al.
Vaccine (2024) Vol. 42, Iss. 24, pp. 126294-126294
Closed Access | Times Cited: 4
David W. Hutton, Lisa A. Prosser, Angela M. Rose, et al.
Vaccine (2024) Vol. 42, Iss. 24, pp. 126294-126294
Closed Access | Times Cited: 4
Respiratory Syncytial Virus Vaccines: Analysis of Pre-Marketing Clinical Trials for Immunogenicity in the Population over 50 Years of Age
Georgios Papazisis, Xanthippi Topalidou, Georgia Gioula, et al.
Vaccines (2024) Vol. 12, Iss. 4, pp. 353-353
Open Access | Times Cited: 2
Georgios Papazisis, Xanthippi Topalidou, Georgia Gioula, et al.
Vaccines (2024) Vol. 12, Iss. 4, pp. 353-353
Open Access | Times Cited: 2
The respiratory syncytial virus vaccines are here: Implications for solid organ transplantation
Paul Trubin, Marwan M. Azar, Camille N. Kotton
American Journal of Transplantation (2024) Vol. 24, Iss. 6, pp. 897-904
Closed Access | Times Cited: 1
Paul Trubin, Marwan M. Azar, Camille N. Kotton
American Journal of Transplantation (2024) Vol. 24, Iss. 6, pp. 897-904
Closed Access | Times Cited: 1
Respiratory syncytial virus vaccination strategies for older Canadian adults: a cost-utility analysis
Ashleigh R. Tuite, Alison E. Simmons, Monica Rudd, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Ashleigh R. Tuite, Alison E. Simmons, Monica Rudd, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Altered epidemiological patterns of Respiratory Syncytial Virus and influenza detections in a tropical Australian setting 2020 to 2023
Joanne C Nixon, Kevin B. Freeman, Rob Baird
Australian and New Zealand Journal of Public Health (2024) Vol. 48, Iss. 4, pp. 100172-100172
Closed Access | Times Cited: 1
Joanne C Nixon, Kevin B. Freeman, Rob Baird
Australian and New Zealand Journal of Public Health (2024) Vol. 48, Iss. 4, pp. 100172-100172
Closed Access | Times Cited: 1
Influential drivers of the cost-effectiveness of respiratory syncytial virus vaccination in European older adults: A multi-country analysis
Xiao Li, Lander Willem, Caroline Klint Johannesen, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Xiao Li, Lander Willem, Caroline Klint Johannesen, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Cost-Effectiveness of Vaccinating Adults Aged 60 Years and Older Against Respiratory Syncytial Virus
David W. Hutton, Lisa A. Prosser, Angela M. Rose, et al.
(2024)
Closed Access
David W. Hutton, Lisa A. Prosser, Angela M. Rose, et al.
(2024)
Closed Access
Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Prefusion F Vaccine for Prevention of Respiratory Syncytial Virus Among Older Adults in Greece
George Gourzoulidis, C. Tzanetakos, Argyro Solakidi, et al.
Vaccines (2024) Vol. 12, Iss. 11, pp. 1232-1232
Open Access
George Gourzoulidis, C. Tzanetakos, Argyro Solakidi, et al.
Vaccines (2024) Vol. 12, Iss. 11, pp. 1232-1232
Open Access
